Brian Krueger, PhD, is an Associate Vice President and Technical Director in R&D at Labcorp. His areas of focus are high throughput exome and genome sequencing, Molecular Microbiology, and high throughput lab automation. He and the Molecular Microbiology R&D group at Labcorp developed and received FDA Emergency Use Authorization for the LabCorp COVID-19 RT-PCR Test. Recently, Labcorp was awarded a SARS-CoV-2 sequencing surveillance contract with the CDC as a direct result of the R&D team's work in sequencing and characterizing thousands of viral genomes from early on in the pandemic. Dr. Krueger received his PhD in Molecular and Cellular Biology from the University of Iowa in 2009. He then spent 3 years at the University of Florida employing genetic manipulation and high throughput sequencing techniques to create hundreds of viral mutants of Kaposi Sarcoma Herpesvirus and Murine Herpesvirus 68. In 2012, Dr. Krueger transitioned from viruses to humans and spent 3 years overseeing Dr. David Goldstein's high throughput human genetics sequencing lab at Duke University and transitioned that lab to Columbia University Medical Center in 2014. He joined Labcorp in 2015 where he has continued to focus on diagnostic assay development in both rare disease genetics and infectious disease.